Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning, happy Friday! Let’s get into the news.
Otsuka tops Vera Therapeutics in kidney disease study showdown
From STAT’s Adam Feuerstein: Another example of why biotech is a tough business.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
View All Plans
